Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valsartan + Rosuvastatin FDC for Hypertension and Dyslipidemia
NCT02662894Phase 3Withdrawn
- Sponsor
- EMS
- Start
- Oct 2019
- Primary completion
- Sep 2020
- Modality
- Orthosteric Ligands
01
Overview
Phase 3, randomised, open-label trial of valsartan and rosuvastatin in hypertension (HTN) and dyslipidemia (4 arms), sponsored by EMS. Primary endpoints: Reduction of systemic blood pressure at 8 weeks and Percentage of participants who reach the goal of LDL-C at 8 weeks. Planned start Oct 2019; status: withdrawn.
02
Drugs
valsartanrosuvastatin
03
Conditions
hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on NCT02662894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02662894.